Previous 10 | Next 10 |
2023-04-06 05:20:37 ET Curis ( NASDAQ: CRIS ) said a new employee will be granted stock options to buy 135.45K common shares of the company. The inducement grant has an exercise price equal to the closing price of the common stock on March 31, the company added. The s...
Curis to Present at Upcoming Healthcare Conferences in April PR Newswire LEXINGTON, Mass. , April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ...
2023-03-13 12:22:06 ET Curis, Inc. (CRIS) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer James Dentzer - President and Chief Executive Officer Robert Martell - Head of R&D Confere...
2023-03-13 08:02:48 ET Curis press release ( NASDAQ: CRIS ): Q4 GAAP EPS of -$0.12 beats by $0.01 . Revenue of $2.89M (-8.0% Y/Y) misses by $0.37M . As of December 31, 2022, Curis's cash, cash equivalents and investments totaled $85.6 million, and the Company...
Curis Provides Fourth Quarter 2022 Business Update PR Newswire Curis completes enrollment of the 9 additional patients requested by FDA ahead of schedule in its TakeAim Leukemia study Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass....
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call PR Newswire LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of c...
2023-03-08 17:35:28 ET Major earnings expected after the bell on Thursday include: Oracle corporation ( ORCL ) DocuSign ( DOCU ) Wheaton Precious Metals Corp. ( WPM ) Bionano Genomics ( BNGO ) Ulta Beauty (ULTA0) For further details see: ...
Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023 PR Newswire LEXINGTON, Mass. , March 2, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics...
Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS PR Newswire 29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutat...
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia PR Newswire Curis to review results during conference call, featuring commentary by Dr. Eric Winer , M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...